AptarGroup

Industry & manufacturing / Packaging Solutions and Dispensing

🚀 Founded 1992 🌎 USA 🏷️ ATR US0383361039 ⭐ 1000 DCF 117.49 💰153.18

ℹ️ Info

🧾 At a Glance 📎 Core Facts 🛍️ Products/Services ⭐ Ratings 🧑‍💼 Executives 💬 My Comments

💡 Analytics

🔔 Insights 🏢 Company Q&A (464) 🛠️ Industry Q&A (98) 🏁 Competitors 📊 Price Low 📈 Price Swings ⚡ SWOT 🏛️ PEST 🌀 Porter's Five Forces ✨ Score Positive ⚠️ Risk Assessment 🧩 Segmentation 🅶 Google Links

💸 Financials

⚖️ Balance Sheet 💵 Income Statement 🔄 Cash Flow 👑 Owner Earnings

📊 Ratios

💰 Margins 📐 Financial Ratios 🌱 Growth 📏 Enterprise Value 📌 Key Metrics 💵 Dividends

🔧 Tools

✅ Due Diligence

📚 Resources

📰 News 🔶 Clusters 🗂️ SEC Filings 🔢 Stock Split History 📢 Press Releases 👤 Insider Trades 📅 Earnings Calendar 🌐 Web 📝 Reports

📢 Press Releases

[ Disclaimer ]

Date	Press release
2025-05-29 17:00:00	Aptar Releases 2024 Corporate Sustainability Report Crystal lake, ill.--(business wire)--aptargroup, inc. (nyse: atr), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2024 corporate sustainability report entitled progress takes shape. aptar’s report highlights key milestones of its global sustainability strategy across the company’s global operations focused on three key pillars: care - operating with care for employees, communities and the environment by aiming to continuously impr.
2025-05-01 17:03:00	Aptar Reports First Quarter 2025 Results Crystal lake, ill.--(business wire)--aptar reports first quarter 2025 results.
2025-05-01 16:15:00	Cytosorbents Provides Regulatory Update For Drugsorb-atr Princeton, n.j., may 1, 2025 /prnewswire/ -- cytosorbents corporation (nasdaq: ctso), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for drugsorb™-atr, its fda-designated breakthrough device.
2025-04-29 10:00:00	Rakovina Therapeutics Showcases Preclinical Results Of Novel Ai-discovered Cancer Therapies At Aacr 2025 Data highlights novel parp1 and atr inhibitors with progress toward next-generation therapies for hard-to-treat malignancies data highlights novel parp1 and atr inhibitors with progress toward next-generation therapies for hard-to-treat malignancies
2025-04-17 17:00:00	Aptar Declares Quarterly Dividend Crystal lake, ill.--(business wire)--aptar declares quarterly dividend.
2025-04-15 17:00:00	QXB0YXIgUm VjZWl2ZXMg UGxhdGludW 0gUmF0aW5n IEZyb20gRW NvdmFkaXMg Rm9yIFRoZS BGaWZ0aCBD b25zZWN1dG l2ZSBZZWFy Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIHJl Y2VpdmVzIH BsYXRpbnVt IHJhdGluZy Bmcm9tIGVj b3ZhZGlzIG ZvciB0aGUg ZmlmdGggY2 9uc2VjdXRp dmUgeWVhci 4=
2025-04-08 12:00:00	VGVjaG5pcC BFbmVyZ2ll cyBBd2FyZG VkIE1ham9y IENvbnRyYW N0IEZvciBC bHVlIFBvaW 50IE51bWJl ciBPbmUgQX RyLCBUaGUg V29ybGTigJ lzIExhcmdl c3QgTG93LW NhcmJvbiBB bW1vbmlhIF Byb2R1Y3Rp b24gRmFjaW xpdHk= VGVjaG5pcC BlbmVyZ2ll cyAocGFyaX M6dGUpIGhh cyBiZWVuIG F3YXJkZWQg YSBtYWpvci ggMSkgY29u dHJhY3QgYn kgYmx1ZSBw b2ludCBudW 1iZXIgb25l LCBhIGpvaW 50IHZlbnR1 cmUgYmV0d2 VlbiBjZiBp bmR1c3RyaW VzLCBqZXJh LCBhbmQgbW l0c3VpICYg Y28sIGZvci B0aGUgYmx1 ZSBwb2ludC BudW1iZXIg b25lIGF0ci Bwcm9qZWN0 IGluIGRvbm FsZHNvbnZp bGxlLCBsb3 Vpc2lhbmEu IHRoaXMgcH JvamVjdCBh aW1zIHRvIG RlbGl2ZXIg dGhlIHdvcm xk4oCZcyBs YXJnZXN0IG xvdy1jYXJi b24gYW1tb2 5pYSBwbGFu dCB3aXRoIG EgY2FwYWNp dHkgb2YgYX Bwcm94aW1h dGVseSAxLj QgbWlsbGlv biBtZXRyaW MgdG9ucyBw ZXIgeWVhci 4=
2025-03-20 17:00:00	QXB0YXIgUm Vjb2duaXpl ZCBXaXRoIF ByZXN0aWdp b3VzIOKAmW HigJkgU2Nv cmUgT24gVG hlIENkcCBD bGltYXRlIE NoYW5nZSBB c3Nlc3NtZW 50 Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIHJl Y29nbml6ZW Qgd2l0aCBw cmVzdGlnaW 91cyDigJhh 4oCZIHNjb3 JlIG9uIHRo ZSBjZHAgY2 xpbWF0ZSBj aGFuZ2UgYX NzZXNzbWVu dC4=
2025-02-06 17:17:00	QXB0YXIgUm Vwb3J0cyBG b3VydGggUX VhcnRlciBB bmQgQW5udW FsIDIwMjQg UmVzdWx0cw == Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIHJl cG9ydHMgZm 91cnRoIHF1 YXJ0ZXIgYW 5kIGFubnVh bCAyMDI0IH Jlc3VsdHMu
2025-01-23 17:00:00	QXB0YXIgRG VjbGFyZXMg UXVhcnRlcm x5IERpdmlk ZW5kIEFuZC BBbm5vdW5j ZXMgMjAyNS BBbm51YWwg TWVldGluZy BEZXRhaWxz Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIGRl Y2xhcmVzIH F1YXJ0ZXJs eSBkaXZpZG VuZCBhbmQg YW5ub3VuY2 VzIDIwMjUg YW5udWFsIG 1lZXRpbmcg ZGV0YWlscy 4=
2025-01-08 17:00:00	QXB0YXIgQW 5ub3VuY2Vz IDIwMjUgUX VhcnRlcmx5 IENvbmZlcm VuY2UgQ2Fs bCBEYXRlcw == Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIGFu bm91bmNlcy AyMDI1IHF1 YXJ0ZXJseS Bjb25mZXJl bmNlIGNhbG wgZGF0ZXMu
2025-01-06 17:00:00	QXB0YXIgVG 8gUHJlc2Vu dCBBdCA0M3 JkIEFubnVh bCBKLnAuIE 1vcmdhbiBI ZWFsdGhjYX JlIENvbmZl cmVuY2UgT2 4gSmFudWFy eSAxNiwgMj AyNQ== Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIHRv IHByZXNlbn QgYXQgNDNy ZCBhbm51YW wgai5wLiBt b3JnYW4gaG VhbHRoY2Fy ZSBjb25mZX JlbmNlIG9u IGphbnVhcn kgMTYsIDIw MjUu
2024-11-13 17:00:00	QXB0YXIgTm FtZWQgQW1v bmcgVG9wID UwIE9mIFRo ZSDigJh3b3 JsZOKAmXMg VG9wIENvbX BhbmllcyBG b3IgV29tZW 4gMjAyNOKA mSBCeSBGb3 JiZXM= Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIG5h bWVkIGFtb2 5nIHRvcCA1 MCBvZiB0aG Ug4oCYd29y bGTigJlzIH RvcCBjb21w YW5pZXMgZm 9yIHdvbWVu IDIwMjTigJ kgYnkgZm9y YmVzLg==
2024-10-24 17:00:00	QXB0YXIgUm Vwb3J0cyBU aGlyZCBRdW FydGVyIDIw MjQgUmVzdW x0cw== Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIHJl cG9ydHMgdG hpcmQgcXVh cnRlciAyMD I0IHJlc3Vs dHMu
2024-10-22 17:00:00	QXB0YXIgQX dhcmRlZCBG ZWRlcmFsIE dvdmVybm1l bnQgQ29udH JhY3QgVG8g QWR2YW5jZS BOb3ZlbCBT dGVyaWxpem F0aW9uIFRl Y2hub2xvZ3 kgRm9yIE1l ZGljYWwgRG V2aWNlcw== Q3J5c3RhbC BsYWtlLCBp bGwuLS0oYn VzaW5lc3Mg d2lyZSktLW FwdGFyIGF3 YXJkZWQgZm VkZXJhbCBn b3Zlcm5tZW 50IGNvbnRy YWN0IHRvIG FkdmFuY2Ug bm92ZWwgc3 RlcmlsaXph dGlvbiB0ZW Nobm9sb2d5 IGZvciBtZW RpY2FsIGRl dmljZXMu

📰 Browse additional press releases for AptarGroup!

📖 Get insights from "The Checklist Value Investor — A Smarter Way to Pick Stocks" now!

What is special about us?

Newsletter

Imprint

Disclaimer

×
Disclaimer

InsightfulValue is an independent platform dedicated to value investing research. The information provided on this website is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice.
We are not financial advisors, investment consultants, or licensed consultants. Our analyses, insights, and criteria are based on principles learned from renowned value investors such as Benjamin Graham, Warren Buffett, and Charlie Munger, but they should not be considered personalized investment recommendations.
Investing in financial markets carries risks, and past performance is not indicative of future results. Users of this website should conduct their own due diligence and consult with a qualified professional before making any financial or investment decisions. InsightfulValue assumes no liability for any financial losses or decisions made based on the information provided on this site.
By using this website, you acknowledge and accept that all investments involve risk and that InsightfulValue does not guarantee any financial outcomes.

Legal

Due Diligence

To start evaluating the companies of your choice, sign up or log in.